Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS).
about
The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.The social burden and quality of life of patients with haemophilia in Italy.Haemophilia utilization group study - Part Va (HUGS Va): design, methods and baseline data.Costs and utilization of treatment in patients with hemophilia.Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide.Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008.The Utilization of Rehabilitation in Patients with Hemophilia A in Taiwan: A Nationwide Population-Based Study.Understanding patient preferences and willingness to pay for hemophilia therapies.The natural evolution of haemophilia care: developing and sustaining comprehensive care globally.Strategies towards a longer acting factor VIII.Economic burden of high-responding inhibitors in patients with hemophilia A in Taiwan.Barriers and perceived limitations to early treatment of hemophilia.Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia ACost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran.Haemophilia prophylaxis: how can we justify the costs?Factor VIII therapy for hemophilia A: current and future issues.Correlation between dispensed and prescribed doses of factor products for bleeding disorders: can a small, centre-based pharmacy hit the mark?Hemophilia care in China: review of care for 417 hemophilia patients from 11 treatment centers in Shanxi Province.Emergency department utilization by haemophilia patients in United States.Transfusion-transmitted infections in haemophilia patientsUnmeasured costs of haemophilia: the economic burden on families with children with haemophilia.Treatment adherence in hemophilia.Mortality, health care utilization and associated diagnoses in hospitalized patients with haemophilia in the United States: first reported nationwide estimates.Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.A haemophilia disease management programme targeting cost and utilization of specialty pharmaceuticals.Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.Out-of-pocket and catastrophic expenditure on treatment of haemophilia by Indian families.A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study).Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.A haemophilia treatment centre-administered disease management programme in patients with bleeding disorders.Healthcare resource utilization among haemophilia A patients in the United States.
P2860
Q30249256-EFE43B20-60E1-44DB-ABC7-835E81667DCDQ33708947-9E52E740-C3A4-4DED-9EBE-D511662165C0Q33937275-BE727F2F-FB03-4A93-A021-9284DF154D9FQ35821757-911B5AA7-3375-4812-AF43-42C57459628DQ35915662-2D9C9ECA-931B-4B4B-861A-FCAD7BE8CB9DQ35932549-39389CF4-27BB-4DAB-BFE4-E82E5C0746C2Q36149893-F16162CE-3907-406A-A385-1F72B881A021Q36284406-E6E2B5D1-64B7-41DA-9EBA-BC8024ED09FFQ36473025-3886BDD0-7E13-4FEF-B62A-A43EB3010B88Q36473043-73DAE5E9-314F-4EBF-AF90-D61A9B660C71Q36620369-F8AA05A2-456B-4D64-9FB3-D5A96F4688FFQ36863077-5A343DB1-ECA6-46C5-AFBD-628FF642590DQ37303186-2936E88C-0E3B-4F25-93C7-3049701D5B58Q37619008-5AAB8769-6442-4F03-B87B-7F4A22CEA19DQ38002994-37D94457-5F05-4524-BE46-B2C0E342ACB8Q38203350-DA00F3A5-D0B1-424C-8DF8-EDB0090DC8ECQ38259752-1A1F4B75-4CBC-4CAA-AEF8-6548CC6FE210Q38463150-1DBDB28F-DCDC-4454-8B03-EC159695D251Q39149015-E971A917-9594-489F-A830-13E3D59B779CQ41698454-F1310BE9-BE57-49F7-B24E-63C0B5965E74Q41752730-ED377EDE-1964-467A-84F6-D219013ECFE9Q42371331-07A040C9-66D9-4EAE-BB47-19DDACD7954BQ43433675-58A37A45-A4C0-4C7A-AFE3-F2CB1C31E845Q43684691-5167CEF2-D3CF-4E48-8B9E-E506AA2E4F50Q45858388-C97D2235-A0CD-4DFE-884C-A45A62FE2882Q45861755-9BF57837-103C-41D3-AD03-DB96EF9545E9Q45863985-3CEFE60D-3505-40B6-B184-3B230B4B7325Q45865285-5A1C134D-3CCA-4C08-AE33-244372751725Q45866554-B10B1E0D-498E-4C00-A02F-EEA025140A6CQ45868331-CB55C87A-4816-469E-85C4-01F9E8C2506AQ45871210-14B429F9-9719-47D8-A0FB-CC0554ED99A4Q45874612-7F6E0DF5-1A51-49A9-9781-F859BB4C64AF
P2860
Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS).
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Utilization of care in haemoph ...... tilization Group Study (HUGS).
@en
type
label
Utilization of care in haemoph ...... tilization Group Study (HUGS).
@en
prefLabel
Utilization of care in haemoph ...... tilization Group Study (HUGS).
@en
P2093
P2860
P1433
P1476
Utilization of care in haemoph ...... tilization Group Study (HUGS).
@en
P2093
HUGS Steering Committee
M A Koerper
R G Curtis
P2860
P356
10.1111/J.1355-0691.2004.00881.X
P478
10 Suppl 1
P577
2004-03-01T00:00:00Z